Phase III Clinical Trials of Brentuximab Vedotin Continue to Demonstrate Superior Clinical Activity
Additional, updated, analyses of results from ECHELON-1 and ECHELON-2, the frontline phase III trials of brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda), an antibody-drug conjugate or...
Enfortumab Vedotin Produces High Tumor Response in Metastatic Urothelial Cancer
Enfortumab vedotin (also known as ASG-22CE), an investigational antibody-drug conjugates being developed by Seattle Genetics in collaboration with Astellas Pharma, showed a positive, high...
Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 ASCO Annual Meeting
Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates or ADCs targeting cancers in areas of high...
Daiichi Sankyo to Present ADC Pipeline Results
Data for several investigational compounds in the Daiichi Sankyo oncology pipeline will be presented at the upcoming annual meeting of the American Society of...
ASCO 2019 ADC Presentation Guide
We have created the following guide to all presentations related to ADCs for the upcoming ASCO Annual Meeting 2019 taking place at the McCormick...
Phase I Data for SAR408701 Supports Further Development in Lung Cancer
During the upcoming annual meeting American Society of Clinical Oncology (ASCO) in June 2019, Sanofi's oncology franchise will present a renewed strategy to address...
New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers
Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called RC48 being developed by RemeGen...
Sutro Presents Preliminary Results From Ongoing Phase I Study of STRO-001
California-based Sutro Biopharma has confirmed that the company will present preliminary results from the first 14 patients enrolled in the company's ongoing Phase I...
PEGS 2019: Using Economic Modelling In the ADC Manufacturing Supply Chain
Antibody-drug conjugates have become a strong and promising strategy for the treatment of cancer, and, potentially emerging in therapeutic areas outside oncology and hematology.
Today,...
